MY103779A - Cloning and expression of transforming growth factor (beta)2 - Google Patents
Cloning and expression of transforming growth factor (beta)2Info
- Publication number
- MY103779A MY103779A MYPI88001108A MYPI19881108A MY103779A MY 103779 A MY103779 A MY 103779A MY PI88001108 A MYPI88001108 A MY PI88001108A MY PI19881108 A MYPI19881108 A MY PI19881108A MY 103779 A MY103779 A MY 103779A
- Authority
- MY
- Malaysia
- Prior art keywords
- tgf
- mature
- cells
- tamoxifen
- transcripts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
cDNA CLONES CODING FOR TGF-?2 WHICH ARE USED TO CONSTRUCT EXPRESSION VECTORS CAPABLE OF DIRECTING THE HIGH-LEVEL EXPRESSION OF MATURE, BIOLOGICALLY ACTIVE TGF-?2 IN TRANSFECTED CHINESE HAMSTER OVARY CELLS (CHO CELLS) ARE DESCRIBED. THE TGF-?2 PRODUCED AND SECRETED BY CHO TRANSFECTANTS HAS A SPECIFIC ACTIVITY ESTIMATED TO BE ABOUT HALF THAT OF RECOMBINANT TGF-?1. THE CLONES WERE ISOLATED FROM A TAMOXIFEN-TREATED HUMAN PROSTATIC ADENOCARCINOMA CELL LINE (PC-3) USING OLIGONUCLEOTIDE PROBES BASED ON THE PARTIAL MONKEY CELL LINE, BSC-40. THE cDNA SEQUENCES PREDICT THAT TGF-?2 IS SYNTHESIZED AS POLYPEPTIDE PRECURSOR FORMS FROM WHICH THE MATURE 112 AMINO ACID TGF-?2 SUBUNIT IS DERIVED BY PROTEOLYTIC CLEAVAGE. THE PROTEINS CODED FOR BY THE HUMAN TGF-?1 AND TGF-?2 cDNAS SHOW AN OVERALL HOMOLOGY OF 41THE MATURE AND AMINO-TERMINAL PRECURSOR REGIONS SHOW 71AND 31HOMOLOGY RESPECTIVELY. NORTHERN BLOT ANALYSIS IDENTIFIED TGF-?2 TRANSCRIPTS OF 4.1 KB, 5.1 KB, AND 6.5KB USING mRNA FROM SEVERAL DIFFERENT SOURCES. ANALYSIS OF POLYADENYLATED RNA FROM TAMOXIFEN-TREATED PC-3 CELLS SHOWED THAT THESE CELLS CONTAIN HIGHER AMOUNTS OF TGF-?1 TRANSCRIPTS THAN TGF-?2, ALTHOUGH THEY PRODUCE MORE TGF-?2 PROTEIN THAN TGF-?1. THIS SUGGESTS THAT THERE IS A POST-TRANSCRIPTIONAL LEVEL OF REGULATION FOR THE PRODUCTION OF THESE PROTEINS.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10675287A | 1987-10-06 | 1987-10-06 | |
| US14826788A | 1988-01-25 | 1988-01-25 | |
| US23406588A | 1988-08-18 | 1988-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY103779A true MY103779A (en) | 1993-09-30 |
Family
ID=27380183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI88001108A MY103779A (en) | 1987-10-06 | 1988-10-04 | Cloning and expression of transforming growth factor (beta)2 |
Country Status (22)
| Country | Link |
|---|---|
| JP (1) | JPH02444A (en) |
| KR (1) | KR970001236B1 (en) |
| CN (1) | CN1035845A (en) |
| AT (1) | AT398433B (en) |
| BE (1) | BE1002693A5 (en) |
| CH (1) | CH680002A5 (en) |
| DE (1) | DE3833897C2 (en) |
| DK (1) | DK556388A (en) |
| ES (1) | ES2012556A6 (en) |
| FI (1) | FI884546A7 (en) |
| FR (1) | FR2621324B1 (en) |
| GB (1) | GB2210620B8 (en) |
| GR (1) | GR1000492B (en) |
| IE (1) | IE60918B1 (en) |
| IL (1) | IL87877A0 (en) |
| IT (1) | IT1227957B (en) |
| MY (1) | MY103779A (en) |
| NL (1) | NL8802442A (en) |
| NO (1) | NO884429L (en) |
| NZ (1) | NZ226486A (en) |
| PT (1) | PT88670B (en) |
| SE (1) | SE8803528L (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5221620A (en) * | 1987-10-06 | 1993-06-22 | Oncogen | Cloning and expression of transforming growth factor β2 |
| US5445941A (en) * | 1993-06-21 | 1995-08-29 | Eli Lilly And Company | Method for screening anti-osteoporosis agents |
| CN100389120C (en) * | 2005-04-12 | 2008-05-21 | 中国人民解放军第三军医大学野战外科研究所 | Sealing TGF-betal antisensedingonucleotides and its use in preparing medicine for treating fibrillation related disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0169016B2 (en) * | 1984-07-16 | 2004-04-28 | Celtrix Pharmaceuticals, Inc. | Polypeptide cartilage-inducing factors found in bone |
| IL78197A (en) * | 1985-03-22 | 1991-07-18 | Genentech Inc | Nucleic acid encoding tgf-beta and its uses |
| PT86144B (en) * | 1986-11-17 | 1990-08-31 | Sandoz Sa | A process for the preparation of a protein having similar activity to the human G-TSF factor and of pharmaceutical compositions containing the same |
| US4931548A (en) * | 1987-01-30 | 1990-06-05 | Techne Corporation | Heterodimer form of transforming growth factor-beta |
| WO1988005787A1 (en) * | 1987-01-30 | 1988-08-11 | Techne Corporation | Transforming growth factor-beta |
| AU1539188A (en) * | 1987-05-04 | 1988-11-10 | Bristol-Myers Squibb Company | TGF-B2 and novel compositions having anti-neoplastic activity |
-
1988
- 1988-09-29 IL IL87877A patent/IL87877A0/en active Protection Beyond IP Right Term
- 1988-10-03 FI FI884546A patent/FI884546A7/en not_active IP Right Cessation
- 1988-10-04 MY MYPI88001108A patent/MY103779A/en unknown
- 1988-10-04 PT PT88670A patent/PT88670B/en not_active IP Right Cessation
- 1988-10-05 KR KR1019880012986A patent/KR970001236B1/en not_active Expired - Lifetime
- 1988-10-05 AT AT0245488A patent/AT398433B/en not_active IP Right Cessation
- 1988-10-05 CH CH3702/88A patent/CH680002A5/fr not_active IP Right Cessation
- 1988-10-05 NO NO88884429A patent/NO884429L/en unknown
- 1988-10-05 NL NL8802442A patent/NL8802442A/en not_active Application Discontinuation
- 1988-10-05 FR FR8813046A patent/FR2621324B1/en not_active Expired - Fee Related
- 1988-10-05 BE BE8801141A patent/BE1002693A5/en not_active IP Right Cessation
- 1988-10-05 SE SE8803528A patent/SE8803528L/en not_active Application Discontinuation
- 1988-10-05 DE DE3833897A patent/DE3833897C2/en not_active Expired - Fee Related
- 1988-10-05 ES ES8803023A patent/ES2012556A6/en not_active Expired - Lifetime
- 1988-10-05 CN CN88109075A patent/CN1035845A/en active Pending
- 1988-10-05 GR GR880100660A patent/GR1000492B/en unknown
- 1988-10-05 DK DK556388A patent/DK556388A/en not_active Application Discontinuation
- 1988-10-05 IE IE301888A patent/IE60918B1/en not_active IP Right Cessation
- 1988-10-06 IT IT8822213A patent/IT1227957B/en active
- 1988-10-06 GB GB8823448A patent/GB2210620B8/en not_active Expired - Fee Related
- 1988-10-06 NZ NZ226486A patent/NZ226486A/en unknown
- 1988-10-06 JP JP63251011A patent/JPH02444A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB2210620B (en) | 1992-07-08 |
| GB8823448D0 (en) | 1988-11-16 |
| IT1227957B (en) | 1991-05-20 |
| NL8802442A (en) | 1989-05-01 |
| SE8803528L (en) | 1989-04-07 |
| DK556388D0 (en) | 1988-10-05 |
| FR2621324A1 (en) | 1989-04-07 |
| SE8803528D0 (en) | 1988-10-05 |
| IL87877A0 (en) | 1989-03-31 |
| KR890006814A (en) | 1989-06-16 |
| NO884429D0 (en) | 1988-10-05 |
| BE1002693A5 (en) | 1991-05-07 |
| DK556388A (en) | 1989-04-07 |
| DE3833897A1 (en) | 1989-05-03 |
| IE60918B1 (en) | 1994-08-24 |
| IT8822213A0 (en) | 1988-10-06 |
| AT398433B (en) | 1994-12-27 |
| ES2012556A6 (en) | 1990-04-01 |
| GB2210620B8 (en) | 1995-07-17 |
| FR2621324B1 (en) | 1994-02-18 |
| ATA245488A (en) | 1994-04-15 |
| IE883018L (en) | 1989-04-06 |
| CN1035845A (en) | 1989-09-27 |
| GR1000492B (en) | 1992-07-30 |
| FI884546A7 (en) | 1989-04-07 |
| JPH02444A (en) | 1990-01-05 |
| CH680002A5 (en) | 1992-05-29 |
| DE3833897C2 (en) | 1997-03-20 |
| KR970001236B1 (en) | 1997-02-04 |
| NZ226486A (en) | 1991-08-27 |
| FI884546A0 (en) | 1988-10-03 |
| NO884429L (en) | 1989-04-07 |
| PT88670B (en) | 1992-12-31 |
| GB2210620A (en) | 1989-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hurwitz et al. | ENDOCRINE-AND AUTOCRINE-MEDIATED REGULATION OF RAT OVARIAN (THECA-INTERSTITIAL) INTKRLEUKIN-β GENE EXPRESSION: GONADOTROPIN-DEPENDENT PREOVIILATORY ACQUISITION | |
| US5330971A (en) | Growth hormone fusion proteins, methods of production, and methods of treatment | |
| NZ237661A (en) | Growth regulatory proteins (epithelins) their production and diagnostic and therapeutic uses | |
| GB2147902B (en) | Microbially produced bgh and its use | |
| BG38166A3 (en) | METHOD FOR OBTAINING A POLYPEPTIDE INCLUDING EXPRESSION OF ITS HETEROLOGOUS GENE FROM A RECOMBINANT MICROBIAL CLONING VECTOR | |
| MY101971A (en) | Cdna clones coding for polypeptides exhibiting human granulocyte macrophage and eosinophil cellular growth factor activity. | |
| CA1339859C (en) | Dna clone of human skin fibroblast collagenase enzyme | |
| MY103779A (en) | Cloning and expression of transforming growth factor (beta)2 | |
| WO1986005805A1 (en) | A dna sequence | |
| EP0261625A3 (en) | Human b-cell differentiation factor and process of producing said factor | |
| Hatsuzawa et al. | Purification of mouse Ren 2 prorenin produced in Chinese hamster ovary cells | |
| Troxell et al. | Sequence and genomic organization of the Drosophila proteasome PROS-Dm25 gene | |
| EP0192743A4 (en) | Modified insulin precursors products and processes. | |
| Cludts et al. | Sequence of bovine interleukin 7 | |
| CA2253233A1 (en) | Process for producing maturation bone morphogenetic protein | |
| HUT66624A (en) | Novel cytokine | |
| Kuga et al. | Effect of N-terminal deletion of signal peptide on the secretion of human granulocyte-colony stimulating factor in mammalian cells | |
| Tsuji et al. | Structural and biological identity of recombinant EDF (erythroid differentiation factor) with natural EDF | |
| JPS6474989A (en) | Dna to code human lysozyme | |
| JPH04501064A (en) | growth hormone fusion protein |